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ABSTRACT 
 
Calyculin C and Amphotericin B are biologically active natural products. 
Amphotericin B is an antifungal agent, which has been a widely used drug in 
antifungal chemotherapy. Calyculin C is a potent protein phosphatase inhibitor 
and plays an important role in cancer research.  
Calyculin C and Amphotericin B contain a stereotetrad fragment. The 
synthesis of the syn, anti, anti stereotetrad of Amphotericin B was based on 
the thiopyranone ring and a chiral auxiliary strategies. The synthesis began 
with the introduction of the asymmetry into the thiopyranone ring via a tartrate 
derived chiral ortho ester, followed by a highly diastereoselective Mukaiyama 
aldol reaction and 1,3-syn diol reduction. The synthesis was complete in only 
six steps with reasonable yield and diastereoselectivity.  
The all-anti stereotetrad of Calyculin C was first approached through a 
convergent strategy but it yielded a wrong diastereomer as the major product. 
The linear synthesis began with a chiral boron crotylation followed by 
ozonolysis. The second crotylation with (Z)-crotyl trifluorosilane produced the 
desired anti, anti, anti stereochemistry with high diastereoselectivity.  
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SYMBOLS AND ABBREVIATIONS 
 
Ac   acetyl 
Bz   benzoyl 
BINAP  2,2'-(bisphenylphosphino)-1,1'-binaphthyl 
Bn    benzyl 
Bu   butyl 
t-Bu   tert-butyl 
Chx(= c-Hex) cyclohexyl 
CSA    camphorsulfonic acid 
DDQ    dicyclohexylcarbodiimide 
de   diastereomeric excess 
DET    diethyl tartrate 
(DHQD)2PHAL dihydroquinidine 1,4-phthalazinediyl diether 
(DHQD)2PYR dihydroquinidine 2,5-diphenyl-4,6-pyrimidinediyl diether 
DHP   3,4-dihydro-2H-pyran 
DIBAL-H   diisobutylaluminum hydride 
DIPA   diisopropyl amine 
DIPEA   diisopropylethylamine (Hünig's base) 
DIPT    diisopropyl tartrate 
DMAP   4-N,N-dimethylaminopyridine 
DME   ethylene glycol dimethyl ether 
DMF    N,N-dimethylformamide 
DMSO   dimethyl sulfoxide 
dppf   1,1’-bis(diphenylphosphanyl)ferrocene 
EDAC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 
 
ee   enantiomeric excess 
Et   ethyl 
HMPA   hexamethylphosphoric triamide (Me2N)3P=O 
IBX    o-iodoxybenzoic acid 
IPA   isopropyl alcohol 
Ipc    isopinocampheyl 
KHMDS   potassium hexamethyldisilazide 
L-Selectride  lithium tri-sec-butylborohydride 
LDA    lithium diisopropylamide 
LiHMDS   lithium hexamethyldisilazide 
MCPBA  m-chloroperoxybenzoic acid 
Me   methyl 
MEM    methoxyethoxymethyl 
MOM    methoxymethyl 
MoOPH  oxodiperoxymolybdenum(pyridine)hexamethyl-
phosphoramide 
Ms   mesyl (methanesulfonyl) 
MS   molecular sieves 
NMO    N-methylmorpholine N-oxide 
Pd2(dba)3  tris(dibenzylideneacetone)dipalladium 
Ph   phenyl 
Piv    pivaloyl 
PMB    p-methoxybenzyl 
PMP    p-methoxyphenyl 
PPTS   pyridinium p-toluenesulfonate 
i-Pr    iso-propyl 
Pyr   pyridine 
Red-Al   sodium dihydrobis(2-methoxyethoxy) aluminate 
rt   room temperature 
TBAF    tetrabutylammonium fluoride 
TBAI    tetrabutylammonium iodide 
TBDPS   t-butyldiphenylsilyl 
TBHP   t-butyl hydroperoxide 
 
 
TBS=TBDMS  t-butyldimethylsilyl 
TEMPO  2,2,6,6-tetramethyl-1-piperidinyloxy 
TES    triethylsilyl 
Tf   trifluoromethanesulfonyl 
TFA    trifluoroacetic acid 
THF    tetrahydrofuran(yl) 
THP    tetrahydropyranyl 
TIPS    triisopropylsilyl 
TMEDA  N,N,N',N'-tetramethylethylenediamine 
TPAP   tetra-n-propylammonium perruthenate 
Tr    trityl 
Ts    p-toluenesulfonyl 
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PREFACE 
 
Amphotericin B is a macrolide polyketide originally isolated from 
Streptomyces nodosus in 1956. Amphotericin B is a potent antifungal agent, 
which makes it an important target molecule for organic chemists. 
Calyculin C is a highly cytotoxic polyketide metabolite isolated from the 
marine sponge Discodermia calyx by Fusetani et al. It has proven to be a 
strong serine/threonine protein phosphatase inhibitor and based on this 
property, might be a potential anti-cancer agent. 
In chapter 1 naturally occurring polyketides are introduced. Chapter 2 deals 
with asymmetric syntheses of polyketide stereotetrads. Six different natural 
polyketides have been chosen to represent seven of the eight possible 
diastereomeric stereotetrads (the syn, syn, anti stereotetrad is a very 
uncommon structure in natural polyketides). The syntheses of the stereotetrad 
fragments, including my own synthesis of the dipropionate fragment of 
Amphotericin B, are discussed in detail. In chapter 3, my synthetic efforts 
towards the anti, anti, anti dipropionate-lactone fragment of Calyculin C are 
discussed. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
1 Introduction 
 
Polyketides form an enormous class of natural products synthesized by 
bacteria, fungi and plants through a condensation reaction of simple 
carboxylic acids.1 Polyketides vary widely in structure; they can be cyclic, 
acyclic, small, large, simple or complex. They may also be linked to 
different sugars or aminosugars. 
It is quite clear that because polyketides vary so much in structure, they 
also have many different biological activities. Between 5000 and 10000 
polyketides are known and about 1% of them possess drug activity, which 
is 5 times as many as the average in natural products.2 Pharmaceutically 
important polyketide drugs include antibiotics, cancer chemotherapeutics, 
cholesterol lowering agents and antifungals. 
Polyketides can be grouped into smaller subgroups: fatty acids, 
polypropionates and aromatic polyketides.3 Polypropionates are 
furthermore divided in three groups: polyether antibiotics, macrolides and 
spiroketals. These subgroups have structural similarities within each 
group, but there are also several structural features, which are universal 
among all polyketides. 
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Figure 1. Examples of naturally occurring polyketides. 
 
The stereotetrad (Figure 2) is a common substructure in polyketides. Four 
stereogenic centers, next to each other, results in eight possible 
diastereomeric combinations of this structure (Figure 3): anti, anti, anti 
(1a); anti, anti, syn (1b); anti, syn, anti (1c); syn, anti, anti (1d); syn, syn, 
anti (1e); syn, anti, syn (1f); anti, syn, syn (1g) and syn, syn, syn (1h). 
 
R2
OHOH
R1 * * * *
 
 
 
Figure 2. General structure of a stereotetrad. 
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Polyketides containing a fragment like 1a-1d and 1f-1h are abundant in 
nature. These natural products are challenging target molecules for synthetic 
chemists; especially stereocontrol in the synthesis of stereotetrads shown in 
Figure 3 calls for accurate planning and realization in laboratory. 
The stereotetrad 1e proved to be a very uncommon structure in natural 
products. A literature search (Scifinder, Beilstein) returned several hits for this 
syn, syn, anti stereotetrad, but no polyketide with this fragment was found. 
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2 Stereotetrads in natural products 
 
2.1 Ionomycin; anti, anti, anti 
 
Ionomycin (2, Figure 4) belongs to the subgroup of polyether antibiotics. It 
was isolated 1978 from the fermentation broths of Streptomyces congoblatus4 
and its structure, including absolute stereochemistry, was resolved one year 
later.5 Ionomycin is an ionophore, meaning that it chelates various inorganic 
cations and transports them across lipid membranes. This character, 
especially its high affinity for Ca2+ ions, has made it an important molecule in 
neurochemistry research.6
 
O
O
HO
H
OH
OH
OOH HO
O
anti, anti, anti
2: Ionomycin  
 
Figure 4 
 
Three different research groups have published total syntheses of Ionomycin; 
Evans (1990)7, Hanessian (1990)8 and Lautens (2002)9. Each of these 
research groups had their own strategies for the synthesis of the anti, anti, 
anti dipropionate fragment (boxed in Figure 4). 
Hanessian et al. based the synthesis of the stereotetrad fragment on L-
glutamic acid (3) as the chiral progenitor (Scheme 1).8 First, glutamic acid was 
converted to the butyrolactone derivative 4,10 which was then allowed to 
undergo the first conjugate addition.11 The lactone was then treated with 
KHMDS, and the resulting enolate was oxygenated with 
oxodiperoxymolybdenum pyridine to produce the hydroxy lactone 5.10, 11 The 
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trisubstituted lactone was then opened and reduced to produce the acyclic 
diol 6, which was selectively protected and converted to the epoxide 7. The 
epoxide 7 was enlarged to the lactone 8 by acetate extension and the double 
bond was constructed as in the first step a. Then a second conjugate addition 
was conducted followed by an oxidation step leading to a 1:1.7 mixture of 
epimeric alcohols 10 and 11,  the minor epimer 10 being the desired one. 
Lactone 10 was reduced, the primary alcohol 12 was protected as the pivalate 
ester 13, followed by ketal formation, diesterification and Swern oxidation. The 
major epimer 11 was subjected to the same protocol as 10 to afford the 
thermodynamically less stable aldehyde 16. Aldehyde 16 was equilibrated to 
the desired aldehyde 14, which was the desired stereotetrad fragment in the 
total synthesis of Ionomycin. 
 
O
TBDPSO
O
HO2C CO2H
NH2
3: L-Glutamic acid
O
TBDPSO
O
OH
4 5
TBDPSO
OH
OH O
OTr
O
O
OTr
O
R
R' RO
OH OH
OTr
PivO
OH OH
OTr
OHC
O O
OTr
OHC
O O
OTr
6 8
9: R, R'=H
10: R=OH, R'=H 
11: R=H, R'=OH
12: R=H 13: R=Piv
14
15 16
a b c
d e f
g
h
h
OTr
7O
i
 
 
a) Ref. 10; b) Ref. 10 and 11 c) 1. NaBH4, aq. THF; 2. NaIO4, aq. MeOH d) 1. TrCl, Et3N, 
DMAP, CH2Cl2; 2. MsCl, Et3N, CH2Cl2, then n-Bu4NF, THF e) 1. PhSeCH2CO2H, BuLi; 2. 
EDAC.HCl, DMAP; 3. 30% H2O2, CH2Cl2 f) 1. CuI, MeLi.LiBr, ether, -20 oC; 2. KHMDS, THF, -
78 oC Æ -30 oC, MoOPH g) 1. LiAlH4, THF; 2. pivaloyl chloride, pyridine h) 1. camphorsulfonic 
acid, acetone, 2,2-dimethoxypropane; 2. LiAlH4, THF; 3. oxalyl chloride, DMSO, CH2Cl2, -78 
oC Æ -30 oC i) K2CO3, MeOH. 
 
Scheme 1 
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Evans et al. published the total synthesis of Ionomycin simultaneously with 
Hanessian et al. in 1990.7 Evans used the chiral auxiliary strategy 
(oxazolidinone) for creating the first asymmetric centers (Scheme 2). Their 
previous studies had shown that the aldol addition of boryl enolates derived 
from crotonimide 1712 with aldehydes provided the crystalline syn, α-vinyl 
adducts such as 19.13 The desired syn adduct 19 was obtained also in this 
case. At this point the chiral auxiliary was removed and the aldehyde was 
reduced to the corresponding alcohol 20a. Alcohol 20a was then tosylated 
and the tosylate was reduced with hydride to produce the stereotriad 21 with 
the desired stereochemistry. After oxidation of the double bond with OsO4 two 
epimeric alcohols 22a and 22b were obtained in a 78:22 ratio. Selective 
protection of the primary alcohol with TBDPS group, followed by ketal 
formation and removal of the TBDPS group, produced two separable 
diastereomeric alcohols 24 and 25. The major diastereomer 24 was directly 
oxidized to the desired aldehyde 26. The minor diastereomer 25 was also 
oxidized, after which it was epimerized to produce the thermodynamically 
more stable aldehyde 26. 
 
N
O
O Me
Ph
O
BnO H
O
N
O
O Me
Ph
O
BnO
OH
CH2OR
BnO
OH
BnO
OH
BnO
OH OH
OR BnO
O O
TBDPS
BnO
O O
OH
BnO
O O
OH
BnO
O O
O
BnO
O O
O
17
18
a
19
b c
20a: R=H
20b: R=Ts
21
d
22a,b: R=H
22c,d: R=TBDPS
e
23a,b
f
24
25
26
27
g
g
h
 
 
a) Bu2BOTf, Et3N, CH2Cl2, -78 oC, 18, -78 oC, H2O2, MeOH b) 1. Bu3B, HOAc, THF; 2. LiBH4, 
THF, 0 oC; 3. H2O2, MeOH c) 1. p-TolSO2Cl, pyridine, 5 oC; 2. Li(Et)3BH, THF; 3. H2O2, NaOH 
(aq), MeOH d) 1. OsO4, R3N-O, H2O/Me2CO; 2. TBDPSCl, Et3N, DMAP, CH2Cl2 e) 
Me2C(OMe)2, CSA, acetone f) (n-Bu)4NF, THF g) Pyr.SO3, Et3N, DMSO h) K2CO3, MeOH. 
 
Scheme 2 
 24 
 
The most recent total synthesis of Ionomycin has been published in 2002 by 
Lautens et al.9 Their synthesis was based on the ring-opening methodology, 
which had been developed earlier in their laboratory.14 The synthesis of the 
dipropionate fragment began with the [3.2.1] oxabicyclic alkene 2815, which 
was opened under reductive conditions (Scheme 3). The product, substituted 
cycloheptene 29 was obtained in excellent yield (95%) and enantioselectivity 
(93-95% ee). One stereocenter in 29 needed inversion for achieving the 
desired stereochemistry (Scheme 3, step b). Cycloheptene 30 was then 
opened ozonolytically and reductive work-up produced the diol 31. The 
primary hydroxyl groups were differentiated with the help of PMP-acetal 
formation and finally the free hydroxyl group was oxidized by the Swern 
protocol producing the desired building block 34 with the correct 
stereochemistry. 
 
O
OTIPS
TIPSO
OH
TIPSO
OPMB
HO
OTIPSO O
PMP
HO OH
TIPSO OPMB
TrO OH
TIPSO OPMB
TrO O
TIPSO OPMB
28 29 30
31 32 33
34
a b c
d e
f
 
 
a) Ni(COD)2, (S)-BINAP, toluene, 65 oC, DIBAL-H (added over 20 h) b) 1. DMSO, (COCl)2, 
NEt3, CH2Cl2, -78 oC; 2. toluene, DIBAL-H, -78 oC; 3. THF, KHMDS, PMBCl c) O3, 
MeOH/CH2Cl2, -78 oC then NaBH4, rt d) CH2Cl2, DDQ, mol. sieves e) 1. TrCl, Et3N, DMAP, 
CH2Cl2; 2. CH2Cl2, DIBAL-H, -78 oC -> 0 oC f) DMSO, (COCl)2, NEt3, CH2Cl2, -78 oC. 
 
Scheme 3 
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2.2 Amphotericin B/Amphoteronolide B; syn, anti, anti 
 
Amphotericin B (Figure 5) belongs to the macrolide subgroup of polyketides. It 
was isolated from Streptomyces nodosus in 1956 by Vandeputte et al.16 and 
its stereochemical structure was resolved 15 years later by X-ray analysis.17 
Amphotericin B is a potent antifungal agent and is a widely used drug in 
antifungal chemotherapy.18
 
HO Me
Me O
O
OH
Me
OR
COOH
OH
OHOH
OH
OHOHO
35: Amphotericin B, R=
36: Amphoteronolide, R=H
syn, anti, anti
O
HO
NH2
Me
OH
 
 
Figure 5 
 
K. C. Nicolaou and his group were the first ones to develop a total synthesis 
for Amphotericin B and Amphoteronolide B.19 In their retrosynthetic analysis 
the syn, anti, anti stereotetrad (boxed in Figure 5) was an independent 
building block.20 The keys for asymmetry and stereoselectivity in their 
synthesis of this dipropionate were the chiral starting material (+)-diethyl 
tartrate and Evans aldol methodology21 (Scheme 4). 
The enantiomerically pure epoxide 37 was readily available from (+)-diethyl 
tartrate.20 At first the epoxide 37 was converted to the Evans oxazolidinone 
derivative 38,22 the chiral auxiliary was removed and the aldehyde was 
masked as a t-butyl ester. Finally, the hydroxyl groups were protected and the 
t-butyl ester was successfully reduced to produce the desired aldehyde 40. 
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Ph O
O
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H N
O
O
O
Ph
HO
O
O(+)-DET
OCOtBu
OH
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O
OTHP
TBSO
37 38
39
40
a b c
d
 
 
a) Ref. 20 b) Ref. 20 and 22 c) 1. LiBH4, THF, 0 oC, 0.5 h, then t-BuCOCl, pyridine, 3 h; 2. 
Me2-t-BuSiOTf, 2,6-lutidine, CH2Cl2, 0 oC, 1 h, then AcOH-THF-H2O (3:1:1), 50 oC, 2 h; 3. 
PhSSPh, n-Bu3P, THF, 0-25 oC, 3 h, then Raney Ni, EtOH, 12 h d) 1. dihydropyran, cat. CSA, 
CH2Cl2, 0-25 oC, 3 h; 2. DIBAL-H, CH2Cl2, -78 oC, 0.5 h, then CrO3, HCl.pyr, NaOAc, CH2Cl2, 
25 oC, 4 h. 
 
Scheme 4 
 
The C(33)-C(37) dipropionate fragment of Amphotericin B has been also the 
target for us and Carreira et al. Carreira and Tholander published an 
enantioselective synthesis of this stereotetrad in 2001; the synthesis 
consisted of 14 steps in 16% overall yield.23 Our enantioselective synthesis of 
the C(33)-C(37) fragment of Amphotericin B was published two years later 
and the complete synthesis contained only 6 steps.24  
The synthetic route of Carreira et al. is shown in Scheme 5. The key reactions 
from the stereochemical point of view were steps a (Sharpless asymmetric 
dihydroxylation, >99% ee), d (> 95% de) and g (> 95% ee). Sharpless 
asymmetric dihydroxylation introduced the asymmetry into the molecule (step 
a) after which no extra external chiral information was needed. 
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OEt
O
OEt
OOH
HO
OEt
OOMs
HO
OEt
O
Me
O
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OEt
O
Me
OH
OEt
O O
Ph
O
O O
OH
O O
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d e f g
O X
OSiEt3
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O O X
Pri3Si Et3Si
41 42 43 44
45 46 47 48: R=H
49: R=SiEt3
50: X=OH
51: X=NHNMe2
52: X=NNMe2
53: X=O
h i
 
 
a) (DHQD)2PHAL, K2OsO4.2 H2O, K2CO3, K3Fe(CN)6, MeSO2NH2, t-BuOH/H2O, 0 oC, 48 h b) 
MsCl, pyridine, CH2Cl2, 0 oC, 48 h c) NaH, MeCN, 0-23 oC, 3 h d) [Pd2(dba)3].CHCl3, Bu3P, 
H2O2, Et3N, THF, 23 oC, 3 h e) PhCHO, t-BuOK, THF, 0 oC, 1 h f) 1. Pd(OH)2, H2, EtOH, 23 
oC; 2. TFA/MeCN, 23 oC, 12 h g) 1. LDA, MeI, HMPA/THF, -78 oC, 16 h; 2. 2,6-di(tert-butyl)-4-
methylpyridine, Et3SiOTf, CH2Cl2, -40 oC h) 1. DIBAL-H, THF, -78 oC, 2 h; 2. H2NNMe2, 
TsOH.H2O, EtOH, reflux, 12 h i) 1. (i-Pr)3SiOTf, pyridine, 0-23 oC, 3 h; 2. O3, CH2Cl2, -78 oC, 
Me2S. 
 
Scheme 5 
 
Our synthesis of this syn, anti, anti stereotetrad was based on the thiopyrane 
ring strategy.24,  25 Commercially available tetrahydrothiopyran-4-one was first 
converted to the corresponding silyl enol ether 54 (Scheme 6). The 
asymmetry was then introduced into the ring with the help of the tartrate 
derived orthoester 55. Two diastereomers were obtained in a 3:1 ratio and 
both diastereomers were successfully crystallized from the mixture. An X-ray 
structure of the minor diastereomer revealed the stereochemistry of 56. The 
next aldol reaction via the kinetic silyl enol ether 57 was highly 
diastereoselective (10:1 according to 1H NMR) and the desired aldol product 
58 was obtained in reasonable yield. Finally, 1,3-syn diol reduction and 
removal of the sulfur with Raney Nickel produced the enantiomer of the 
stereotetrad of Amphotericin B. The sole source of asymmetry in the whole 
synthesis was the chiral tartrate derived orthoester 55, which actually worked 
as a chiral auxiliary (masked aldehyde). 
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a) ZnCl2, CH2Cl2, 55, 21 h, rt b) LiHMDS, THF, TMSCl, 1 h, -78 oC -> 0 oC c) CH3CHO, TiCl4, 
CH2Cl2, 5 min., -78 oC d) Et2BOMe, NaBH4, THF/MeOH, 1 h, -78 oC e) Raney Ni, IPA, 24 h, 
70 oC. 
 
Scheme 6 
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Figure 6 
 
A mechanistic proposal for the first reaction step (Scheme 6, step a) is shown 
in Figure 6. Zinc coordinates the enolate and the orthoester near to each 
other and enhances the electrophilicity of the poor orthoester electrophile. The 
orthoester 55 can approach the nucleophilic enolate from the upper (A) or 
lower side (B) of the double bond (Figure 6). When it approaches from the 
upper side, there is only one axial hydrogen in the way. When the electrophile 
comes from the lower side, stereoelectronic interactions interfere in the 
reaction. The non-bonding free electron pairs of the thiopyranone ring sulfur 
and the orthoester repel each other and thus the energy of the transition state 
in case B is higher than in case A. This must be also the explanation for the 
diastereoselectivity. The electrophile’s ester tails have also a small influence 
on the diastereoselectivity: the used i-propyl ester gave the 3:1 ratio while the 
corresponding ethyl ester gave a slightly slower 2.3:1 ratio of the 
diastereomers. 
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2.3 Aplyronine A/B/C; anti, syn, anti and anti, anti, syn 
 
Aplyronines A, B and C (Figure 7), 24-membered marine macrolides, were 
isolated from the sea hare Aplysia kurodai in 1993 by Yamada and co-
workers.26 Aplyronines proved to be bioactive molecules; they have high 
degree of activity towards a variety of tumor cell lines.26,   27
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O OH
OR1
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H
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61: Aplyronine A, R1=                  
R2=H
62: Aplyronine B, R1=H
R2=
63: Aplyronine C, R1=R2=H
O
OMe
NMe2
O
OMe
NMe2
anti, syn, anti
anti, anti, syn  
 
Figure 7 
 
Aplyronines contain three stereotetrads: one with anti, syn, anti and two with 
anti, anti, syn stereochemistries. 
Yamada and his group published the first total synthesis of Aplyronine A in 
1996, only three years after the isolation.27 Their retrosynthetic analysis was 
planned so that each of the three stereotetrads represented an individual 
substructure in the total synthesis. 
The synthesis of the anti, syn, anti stereotetrad (Scheme 7) began with an 
Evans aldol reaction between 64 and 65 in which two new stereogenic 
centers were created. The fourth stereocenter was introduced successfully 
through Sharpless asymmetric epoxidation (Scheme 7, step d). The final 
stages (step e) in the synthesis of the anti, syn, anti dipropionate included 
protection of the hydroxyl groups and conversion of the leftward hydroxyl 
group to the sulfone 73. 
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64
65
66 67: R1= H, R2= N(OMe)Me
68: R1= TBS, R2= N(OMe)Me
69: R1= TBS, R2= H
70: R= COOEt
71: R= CH2OH
72 73
a
b c
d e
 
 
a) Bu2BOTf, Et3N, CH2Cl2, 0 oC, then 65, -78 oC, 3 h-> 0 oC, 20 min b) 1. Me3Al, 
MeONHMe.HCl, THF, toluene, CH2Cl2, -10-> 0 oC, 1.6 h; 2. t-BuMe2SiOTf, 2,6-lutidine, 
CH2Cl2, 0 oC, 1 h; 3. DIBAL-H, THF, hexane, -78 oC, 2 h c) 1. (i-PrO)2P(O)CH2COOEt, t-
BuOK, THF, -78 oC, 1 h-> 0 oC, 1.5 h; 2. DIBAL-H, CH2Cl2, hexane, -78 oC, 1 h d) Ti(O-i-Pr)4, 
(+)-DET, t-BuOOH, 4 Å MS, CH2Cl2, -23 oC, 1 h e) Ref. 27. 
 
Scheme 7 
 
The syntheses of the C(21)-C(27) (Scheme 8) and C(28)-C(34) anti, anti, syn, 
stereotetrads were both also based on the Evans aldol chemistry and the 
Sharpless asymmetric epoxidation.27 The fourth stereogenic center was 
created through nucleophilic attack of methylcuprate into the epoxide 82 to 
produce the desired anti, anti, syn stereochemistry. 
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80: R= COOEt
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d e
 
 
a) Bu2BOTf, Et3N, CH2Cl2, 0 oC, then 75, -78 oC, 2 h-> 0 oC, 2 h b) 1. Me3Al, MeONHMe.HCl, 
THF, toluene, CH2Cl2, -10-> 0 oC, 1.5 h; 2. TESCl, imidazole, DMF, 23 oC, 35 min. 3. DIBAL-
H, THF, hexane, -78 oC, 2 h c) 1. (i-PrO)2P(O)CH2COOEt, t-BuOK, THF, -78 oC, 1.5 h-> 0 oC, 
1.5 h; 2. DIBAL-H, CH2Cl2, hexane, -78 oC, 1.5 h d) Ti(O-i-Pr)4, (-)-DET, t-BuOOH, 4 Å MS, 
CH2Cl2, -23 oC, 2 h e) Ref. 27. 
 
Scheme 8 
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Paterson et al. have also been working on the total synthesis of aplyronines.28 
Although their total synthesis of aplyronines is still incomplete, the syntheses 
of the stereotetrad subunits have been published.28
The synthesis of the anti, syn, anti stereotetrad began with an aldol reaction 
between the E-boron enolate of the chiral precursor 84 and aldehyde 85 
(Scheme 9).28a The desired anti, anti aldol product 86 was obtained with high 
diastereoselection (≤ 97% ds). The ketone was then reduced in a 1,3-anti 
manner to produce the desired anti, syn, anti stereochemistry in 87. 
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84 85 86
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a
b
 
 
a) (c-Hex)2BCl, Et3N, Et2O, 0 oC, 1 h, then –78 oC and 85 -> -20 oC, 12 h, oxidative work-up b) 
SmI2, EtCHO, THF, 0 oC, 15 min., then 86, 0 oC, 2 h. 
 
Scheme 9 
 
Paterson et al. also completed the synthesis of the C(21)-C(34) subunit of 
aplyronines.28b This southern segment contains two anti, anti, syn 
stereotetrads and the syntheses of both dipropionates were based on the 
chiral starting materials (88, 89, 92), diastereoselective aldol reactions (steps 
a and c) and stereoselective 1,3-anti diol reduction (steps d and g) (Scheme 
10). 
 
 33 
 
O
OBz
OTESO
OBz
88
89
90
PMBO H
O
PMBO R
OTES
91
(MeO)2P
OO
OBn
H
O
O
92
OTIPS
O
94
OTIPS
OHOBn OH
OTIPS
OO
BnO
93
95
OH
R
OO
BnO
96: R= CH2OH
97: R=CHO
91 + 97 OTESOO
BnO
R
OAc
98
O OTESOO
BnO
R
OAc
99
OH
a
b
c
d
e
f g
 
 
a) 1. (c-Hex)2BCl, Me2NEt, Et2O, 0 oC, 1h, then –78 oC, 89, -> -20 oC, 16 h; 2. TESOTf, 2,6-
lutidine, CH2Cl2, -78 oC, 2 h b) Ref. 28b c) Sn(OTf)2, Et3N, CH2Cl2, 93, -78 oC, 2 h d) iso-
butyraldehyde, SmI2, THF, 0 oC, 2.5 h e) 1. HF.pyridine, THF, rt, 7 h; 2. cat. TEMPO, 
PhI(OAc)2, rt, 2 h f) Ref. 28b g) SmI2, CH3CHO, THF, -5 oC, 2.5 h. 
 
Scheme 10 
 
Synthetic methodology developed in the laboratory of J. Marshall suited 
perfectly for the synthesis of the stereotetrads of aplyronines.29 The key step 
in the syntheses of the anti, syn, anti (Scheme 11) and both anti, anti, syn 
(Scheme 12) dipropionates was the first reaction; an in situ prepared chiral 
allenylindium reagent reacted with a chiral α-methyl aldehyde (Scheme 11, 
step a; Scheme 12, steps a and c) creating two new stereogenic centers with 
high diastereoselectivity.30 The fourth stereocenter of the stereotetrads was 
created either via Sharpless asymmetric epoxidation (Scheme 11, step c; 
Scheme 12, step f) or by aldol reaction (Scheme 12, step d). In the synthesis 
of the rightward anti, anti, syn stereotetrad, the aldol reaction (Scheme 12, 
step d) produced two separable diastereomers 112 and 113 in a 60:40 ratio. 
The desired diastereomer 113 proved to be the minor one, but the major 
diastereomer 112 was inverted via the Martin-Mitsunobu procedure31 to the 
desired diastereomer 113. 
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a) 1. Pd(dppf)Cl2, InI, THF-HMPA; 2. MOMCl, Bu4NI, i-Pr2Net b) Ref. 29 c) (+)-DIPT, Ti(O-i-
Pr)4, t-BuOOH d) 1. Red-Al, THF; 2. MOMCl, Bu4NI, i-Pr2NEt. 
 
Scheme 11 
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a) 1. Pd(dppf)Cl2, InI, THF-HMPA; 2. MOMCl, Bu4NI, i-Pr2NEt b) Ref. 29 c) 1. Pd(dppf)Cl2, InI, 
THF-HMPA; 2. MOMCl, Bu4NI, i-Pr2Net d) lithiation of 111, then 106, ref. 29 e) ref. 29 f) (-)-
DIPT, Ti(O-i-Pr)4, t-BuOOH g) Zn, MeOH, ∆. 
 
Scheme 12 
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2.4 Stevastelins; anti, syn, syn 
 
Stevastelins (Figure 8) represent a family of novel depsipeptides isolated from 
a culture of Penicillium sp. NK37418632 and they have shown to be potent 
immunosuppressive agents.33
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Figure 8  
 
Two research groups have aimed their studies towards the synthesis of 
stevastelins. Sarabia et al. began the synthesis of the stereotetrad of 
stevastelins with the Evans aldol methodology to create the first two 
stereocenters in a syn manner (Scheme 13).34 The other two stereocenters 
were created via an aldol reaction of the E-boron enolate of 126 and the chiral 
aldehyde 125 (Scheme 13, step c). Only one diastereomer, the desired anti, 
syn, syn product 127 was obtained. 
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a) n-Bu2BOTf, Et3N, CH2Cl2, 0 oC, 0.5 h, then –78 oC, tetradecanal, 12 h b) Ref. 33 c) 126, 
(Chx)2BCl, EtN3, CH2Cl2, 0 oC, 2 h, then –78 oC, 125, 12 h, oxidative work-up. 
 
Scheme 13 
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Chakraborty et al. have reported the synthesis of the subunits of stevastelin 
B.35 Their synthesis began with a Ti(IV) mediated diastereoselective non-
Evans syn aldol reaction36 using a 2-oxazolidinethione based chiral auxiliary37 
(Scheme 14). This reaction produced the desired stereotriad as the only 
isolable diastereomer. The fourth stereocenter was created via nucleophilic 
addition of the long chain Grignard reagent onto the aldehyde 132. The 
diastereoselectivity of this step was low: after purification the desired product 
133 was obtained only in 40% yield. 
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a) TiCl4, DIPEA, CH2Cl2, -78 oC b) 1. NaBH4, EtOH, 0 oC; 2. MeOPhCH(OMe)2, CSA (cat.), 
CH2Cl2; 3. DIBAL-H, CH2Cl2, -78 oC-> 0 oC; 4. Swern oxidation c) CH3(CH2)12MgBr, THF, 0 
oC-> rt. 
 
Scheme 14 
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2.5 Pironetin (PA-48153C); syn, anti, syn 
 
Pironetin (PA-48153C) (Figure 9) was isolated in 1993 independently by two 
Japanese research groups from the fermentation broths of Streptomyces sp. 
NK1095838 and Streptomyces prunicolor PA-48153.39 Pironetin has shown 
immunosuppressive activity towards T and B lymphocytes.39 Also, its potent 
activity as a plant growth regulator has been described by Kobayashi and 
coworkers.38
OOMe OH
Et
O
syn, anti, syn
135: Pironetin  
 
Figure 9 
 
The structure of Pironetin (Figure 9), the unsaturated δ-lactone ring joined to 
the syn, anti, syn stereotetrad, has attracted many research groups since its 
isolation, and several total syntheses have been published so far.  
The first total synthesis of Pironetin by Yasui et al. was published two years 
after its isolation.40 The synthesis of the stereotetrad was very straightforward 
and the keys in the synthesis were the chiral precursor 136, asymmetric 
epoxidation (Scheme 15, step c) and hydroboration (Scheme 15, step g). 
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a) 1. PhCH2OC(=NH)CCl3, CF3SO3H; 2. LiAlH4; 3. Swern oxidation b) 1. 
(CF3CH2O)2P(=O)CH2CO2Me, KN(TMS)2, 18-Crown-6; 2. DIBAL-H c) MCPBA d) Me2CuLi e) 
ref. 39 f) n-BuLi g) B2H6, H2O2. 
 
Scheme 15 
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Gurjar et. al based their synthesis of the dipropionate of Pironetin on the chiral 
precursor 144 and Sharpless asymmetric epoxidation (Scheme 16).41  
 
CH2OH CH2OH
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a c
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a) 1. IBX, DMSO, rt, 30 min.; 2. Ph3=CHCO2Et, benzene, rt, 3 h; 3. DIBAL-H, CH2Cl2, -20 oC, 
30 min b) TBHP, Ti(OiPr)4, (-)-DIPT, CH2Cl2, -20 oC, 20 h c) 1. Me2CuLi, Et2O, -78 oC, 8 h; 2. 
TBSCl, imidazole, CH2Cl2, rt, 3 h; 3. KH, MeI, Et2O, rt, 30 min.; 4. Bu4NF, THF, rt, 2 h d) = a) 
e) 1. TBHP, Ti(OiPr)4, (+)-DIPT, CH2Cl2, -20 oC, 18 h; 2. Red-Al, THF, 0 oC, 4 h. 
 
Scheme 16 
 
Chida et al. began the synthesis of the stereotetrad of Pironetin from L-
quebrachitol 15042 (Scheme 17), which is an optically active cyclitol obtained 
in large quantities from the serum of rubber tree.43 Intermediate 151 was 
prepared stereoselectively from L-quebrachitol 150 in five steps.44 Two 
stereocenters were inverted via base treatment of 151 to produce the epoxide 
152 followed by trans-diaxial opening of the epoxide with the methyl 
nucleophile and protection. Intermediate 153 already had the desired 
stereochemistry. Finally, 153 was deketalized and opened to produce the 
acyclic syn, anti, syn stereotetrad 155 of Pironetin. 
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a) 1. ref. 44; 2. Bu2SnO, MeOH, reflux, then TsCl, DMAP; 3. 1,4-dioxane, rt b) MeONa, 
MeOH, reflux c) 1. Me3Al, CH2Cl2:hexanes, rt; 2. BzCl, pyridine, DMAP, rt d) 10-
caphorsulfonic acid, MeOH, rt e) NaIO4, acetone:H2O, 0 oC, then NaBH4, MeOH, 0 oC. 
 
Scheme 17 
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Watanabe et al. used the chiral precursor 15645 as the starting material in 
their synthesis of the dipropionate fragment of Pironetin (Scheme 18).46 All 
stereochemical information came from the chiral cyclohexanone derivative 
156 and the chiral R* chain, which was coupled to 162 in high yield and 
diastereoselectivity (Scheme 18, step g). 
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a) 1. DHP, PPTS, CH2Cl2, rt; 2. LDA, HMPA, THF, -78 oC, then MeI; 3. L-Selectride, THF, -78 
oC; 4. NaH, MeI, TBAI, THF, 60 oC; 5. aq. HCl, MeOH, 0 oC b) Dess-Martin oxidation c) 1. 
TBSOTf, Et3N, CH2Cl2, 0 oC; 2. cat. OsO4, NMO, THF, H2O, rt d) LHMDS, THF, -78 oC, then 
Li, liq. NH3, then NH4Cl e) Pb(OAc)4, benzene, MeOH, rt f) ref. 45 g) n- BuLi, HMPA, THF, 0 
oC, then R*X h) Hg(CIO4)2, CaCO3, THF, H2O, rt i) LiAlH(OtBu)3, LiI, ether, -78 oC -> 0 oC. 
 
Scheme 18 
 
Keck et al. started their synthesis with chelation controlled (TiCl4) addition of 
(Z)-crotyltri-n-butylstannane 167 to the β-benzyloxy aldehyde 166 to give the 
desired anti, syn homoallylic alcohol 168 (Scheme 19).47 The fourth 
stereocenter of the stereotetrad was created via an aldol reaction between the 
stereotriad aldehyde 169 and the chiral TMS enol ether 170 using BF3.OEt as 
the Lewis acid. The desired diastereomer 171 was the only product in this 
reaction; none of the other diastereomers was detected. 
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a) 1. 167, TiCl4 2. KH, MeI b) ref. 46 c) 170, BF3.OEt. 
 
Scheme 19 
 
The most recently published total synthesis of Pironetin by Dias et al. was 
based on the Evans aldol chemistry (Scheme 20).48 This route was very short 
and efficient but it needed external chiral information twice for building up the 
desired stereochemistry (Scheme 20, steps a and c). 
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a) n-Bu2BOTf, CH2Cl2, Et3N, - 5 oC, then –78 oC, 173 b) ref. 47 c) 1. 176, n-Bu2BOTf, CH2Cl2, 
Et3N, - 5 oC, then –78 oC, 175; 2. LiBH4, THF/MeOH, 0 oC. 
 
Scheme 20 
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2.6 Erythromycin A/B and Erythronolide A/B; syn, syn, syn 
 
Erythromycins (Figure 10, 178, 179), erythronolides (Figure 10, 180, 181) and 
their derivatives belong to macrolide antibiotics. Erythromycin A was isolated 
in the early 50’s by McGuire et al.49 from a strain of Streptomyces erytreus, 
and its complete structure was revealed in 1965 by X-ray analysis.50 The 
antibiotic activity of erythromycins is related to their ability to inhibit ribosomal-
dependent protein biosynthesis.51
For over four decades the challenging structures of erythromycins and 
erythronolides have attracted many research groups,52 but only a few total 
syntheses have been reported so far. In this chapter, the first two and the two 
most recent syntheses of the stereotetrad of erythromycins/erythronolides 
(boxed in Fig. 10) are discussed in detail. 
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Figure 10 
 
E. J. Corey et al. published in 1978 the first total synthesis of (+/-)-
erythronolide B.53 The creation of the syn, syn, syn stereotetrad began from 
dienone 182 (rac.) by hydroboration followed by oxidation, to produce the 
dienone acid 183.54 Treatment with bromine/potassium bromide solution 
yielded the bromo lactone 184, which was then converted under basic 
reaction conditions to the epoxy acid 185. The epoxy acid 185 was then 
converted to the bromo epoxy lactone 186a, from which the bromine was 
cleaved away via radical reaction to produce the epoxy lactone 186b. Epoxide 
186b was opened and the ketone 187 was then stereoselectively reduced 
with Raney Nickel. Then the hydroxyl groups were protected to produce the 
dibenzoate 188, which already possessed the all-syn stereochemistry. 
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Dibenzoate 188 was finally transformed to lactone 190, which was one of the 
key intermediates in the first total synthesis of erythronolide A. 
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a) 1. B2H6, THF, 0-10 oC; 2. Jones chromic acid, 0- -10 oC b) Br2, KBr, H2O c) aq. KOH, THF 
d) Br2, KBr, H2O e) NBu3SnH, AIBN, PhH, f) Al/Hg, THF, H20, 0- -10 oC g) 1. H2, Raney Ni, 
DME, -20 oC; 2. BzCl, pyridine h) LDA, THF, -78 oC, then MeI, HMPA, -78 oC-> -45 oC i) 1. 
LiOH, H2O; 2. CrO3, H2SO4, acetone, -10 oC j) MeCO3H, EtOAc, 55 oC. 
 
Scheme 21 
 
Woodward et al. completed the first (and also the only one, so far) total 
synthesis of Erythromycin A in 1981.52b Thiopyranone ring strategy was the 
key for the successful total synthesis as well as for the synthesis of the syn, 
syn, syn stereotetrad (Scheme 22). 
The synthesis of the syn, syn, syn stereotetrad began from the racemic 
starting materials 191 and 192. The racemic intermediate 193 was allowed to 
undergo an intramolecular aldol reaction catalyzed by D-proline, and a 1:1 
mixture of enantiomerically enriched diastereomers 194a and 194b were 
obtained (36% ee for both diastereomers). The synthesis was continued with 
194b and the enantiomerically enriched enone 195 was obtained after 
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dehydration. The desired enantiomer (+)-195 crystallized out from the 
enantiomeric mixture and the synthesis was continued with optically pure 
material. Then, NaBH4 reduction and OsO4 oxidation gave stereospecifically 
the key intermediate 196 in good yield and stereoselectivity. 
The final stages in building up the all-syn-stereotetrad were very 
straightforward. After desulfurisation, deprotection and oxidation (step f), 
aldehyde 198 was allowed to react with the enolate of tert-butyl 
thiopropionate. The product, the undesired Cram aldol adduct (wrong 
stereochemistry at C2) was finally inverted via kinetic protonation to the 
desired syn, syn, syn product 199. 
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a) 1. NaH, THF, DMSO, rt; 2. AcOH, H2O, rt b) D-Pro, PhH/MeOH, rt c) 1. MsCl, py; 2. Al2O3, 
EtOAc d) 1. NaBH4, MeOH, 0 oC; 2. MeOCH2I, KH, THF; 3. OsO4, Et2O, then NaHSO3, py; 4. 
Me2C(OMe)2, TsOH, CH2Cl2 e) six steps; f) 1. Raney Ni (W2), EtOH, DMF, rfx; 2. o-
NO2PhSeCN, nBu3P, THF, 30% H2O2, THF, rt; 3. O3, MeOH, CH2Cl2, -78 oC, then Me2S, 
NaHCO3 g) 1. EtCOSCMe3, LDA, THF, -110 oC; 2. t-BuLi, THF, -110 oC, then AcOH, -110 oC 
h) 1. t-BuLi, (CH2NMe2)2, THF, -110 oC; 2. AcOH, -110 oC.  
 
Scheme 22 
 
Evans et. al published the total synthesis of 6-deoxyerythronolide B 
(biosynthetic precursor of erythromycins) in 199755 and it is not surprising that 
the synthesis was based on the Evans aldol chemistry. 
The Evans’ all-syn-stereotetrad synthesis was very short and highly 
stereoselective (Scheme 23). The β-ketoimide 200 was allowed to react with 
methacrolein (TiCl4 as the Lewis acid) followed by a 1,3-syn reduction and 
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ketal protection of the diol to produce the stereotetrad 202 in excellent yield 
and stereoselectivity. 
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a) TiCl4, i-Pr2NEt, methacrolein, 0 oC, CH2Cl2 b) 1. Zn(BH4)2, -78 oC, CH2Cl2; 2. Me2C(OMe)2, 
CSA, 25 oC, CH2Cl2. 
 
Scheme 23 
 
The most recent total synthesis of erythromycins was published in 2003 when 
S. F. Martin et al. completed the total synthesis of Erythromycin B.56 The 
synthesis of the syn, syn, syn stereotetrad fragment started with Evans aldol 
chemistry to give the aldol adduct 205 as the only isomer (Scheme 24, step 
a).57 After several reaction steps (Scheme 24, steps b-f), which concentrated 
on the synthesis of the left half of Erythromycin B, two missing stereocenters 
of the syn, syn, syn stereotetrad were created via asymmetric crotylation 
(Scheme 24, step g). 
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a) 204, CH2Cl2, 203; ref. 56 b) LiBH4, THF; ref. 56 c) 1. Br2, MeCN, H2O; 2. Me2CuLi; 3. MeLi, 
CeCl3; ref. 56 d) TMSSCH2CH2STMS, TiCl4; ref. 56 e) ref. 55 f) ref. 55 g) 210, 211, BF3.OEt, 
CH2Cl2, ref. 55. 
 
Scheme 24 
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3 Preparation of the dipropionate-lactone fragment 
of Calyculin C 
 
Calyculins form a class of highly cytotoxic metabolites originally isolated from 
the marine sponge Discodermia calyx by Fusetani et al.58 Calyculins have 
proven to be strong serine/threonine protein phosphatase inhibitors59 and 
based on this property, calyculins might be potential anti-cancer agents.60
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213: Calyculin C  
 
Figure 11 
 
The C9-C19 dipropionate lactone fragment of Calyculin C (boxed in Fig. 11) 
contains seven of the total fifteen stereogenic centers and is thereby a key 
substructure of this sponge metabolite.  
Synthetic efforts towards calyculins have been recently reviewed.61 Several 
syntheses of the lactone-dipropionate fragment have been published with 
varying strategies.62 The most challenging part in the synthesis of this C9-C19 
fragment is the anti, anti, anti stereotetrad, which can be reached either by 
linear62e-d or by convergent62a-c approaches. However, the syntheses 
published so far have many weaknesses (too many steps, poor 
diastereoselectivity or need for inversion of stereocenters). Therefore, new 
routes for this fragment are still needed. 
Our first retrosynthetic analysis of the C9-C19 fragment was based on the 
thiopyranone ring strategy (Scheme 25), but unfortunately it did not lead us 
towards the stereotetrad of Calyculin C. Luckily those studies were not 
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fruitless: the results guided us to a short and enantioselective synthesis of the 
C(33)-C(37) fragment of Amphotericin B.24, 25  
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Scheme 25 
 
The second approach towards the target fragment carried us two steps closer 
to the goal. We succeeded in realizing a short and highly enantio- and 
diastereoselective synthesis of the key intermediate 223 (Scheme 26).63 
Unfortunately, the convergent approach led us to a wrong diastereomer 226 
of C9-C19 fragment of Calyculin C. 
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a) LDA, the ketone 214, 1 h., then the aldehyde 215, THF, -78 oC, 1 h b) MsCl, NEt3, CH2Cl2 
0 oC, 4.5 h c) (DHQD)2PYR, K3Fe(CN)6, K2CO3, NaHCO3, MeSO2NH2, OsO4, H2O/t-BuOH 0 
oC, 17 h d) MeI, Ag2O, Et2O, reflux, 22 h e) L-Selectride, THF, -78 oC, 15 min. f) MEMCl, 
DIPEA, CH2Cl2, reflux, 48 h g) Pd(OH)2/C, EtOH, H2, 40 min. h) TPAP, CH2Cl2, 4 Å MS, 2 h i) 
NEt3, the ketone 224, (Chx)2BCl, Et2O, 0 oC, 1 h, then -78 oC, the aldehyde 223 -> -18 oC, 21 
h j) 1. (Et)2BOMe, NaBH4, THF/MeOH, -78 oC, 4 h; 2. pinacol, MeOH, 40 oC, 72 h. 
 
Scheme 26 
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Figure 12 Crystal structure of the lactone intermediate 218.64
 
Finally, the third plan was successful: a linear approach brought us to the end 
of the synthetic path of the C9-C19 fragment of Calyculin C (Scheme 27).65 The 
lactone aldehyde 223 was first allowed to react with a chiral crotyl borane 
reagent 22766 yielding a 6:1 diastereomeric mixture of two anti homo allylic 
alcohols. The major diastereomer 228 was isolated with simple flash 
chromatography, followed by ozonolysis to yield the unstable β-hydroxy 
aldehyde 229. The second crotylation was realized with Z-crotyl trifluorosilane 
230.67 The reaction succeeded perfectly: only one diastereomer 231 was 
obtained! Finally the diol was converted to the corresponding ketal 232, which 
helped to confirm the stereochemistry of the stereotetrad. 
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a) the crotyl reagent was prepared from (+)-IpcBOMe and trans-butene in THF at -78 oC, then 
BF3.OEt, the aldehyde 223, -78 oC, 1 h, then ethanol amine b) O3, CH2Cl2, -78 oC, then 
triphenyphosphine, rt, 3 h c) the aldehyde 229, 4 Å MS, CH2Cl2, rt, 0.5 h, then 0 oC, DIPEA, 
(Z)- crotyl trifluorosilane 230, 4 h d) 2-methoxy propene, pyridinium p-toluenesulfonate 
(PPTS) (cat.), CH2Cl2, rt, 0.5 h. 
 
Scheme 27 
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4 Conclusions 
 
The stereotetrad is a common substructure in polypropionate natural 
products. Four stereogenic centers next to each other results in eight 
possible diastereomeric combinations of this structure. Thus, an 
asymmetric synthesis of each of these combinations (anti, anti, anti; anti, 
anti, syn; anti, syn, anti; syn, anti, anti; syn, syn, anti; syn, anti, syn; anti, 
syn, syn and syn, syn, syn) demands accurate planning and careful 
realization in laboratory. When the synthesis of a stereotetrad is a part of a 
total synthesis of a more complex molecule the situation becomes even 
more complicated. If the stereotetrad fragment can be cleaved 
retrosynthetically into an independent sub goal, its synthesis is often more 
straightforward than in the case where the stereochemistry of the 
stereotetrad is created by a linear approach. In the latter situation, the 
stereochemistry and structure of the remaining molecule has to be 
considered and it usually limits the possible strategies to minimum. 
Some interesting points can be noted from chapter 2, which deals with 
syntheses of stereotetrads. It was a big surprise to discover, that the linear 
structure of the syn, syn, anti stereotetrad (as a fragment of a natural 
product) was not found with a database search. Even if the conclusion, 
that the syn, syn, anti stereotetrad does not exist in natural products, 
cannot be drawn, it is evident that this structure is very rare in nature. It 
was also interesting to notice that the syntheses of all different 
stereotetrads were mostly based on i) Evans asymmetric aldol 
methodology, ii) Sharpless asymmetric epoxidation and dihydroxylation, iii) 
asymmetric crotylations and iv) diastereoselective aldol reaction between 
an aldehyde and an E-enolate of a ketone. 
The syn, anti, anti dipropionate fragment of Amphotericin B was 
synthesized via thiopyranone ring strategy. The asymmetry was 
introduced into the thiopyranone ring with the chiral tartrate derived 
orthoester 55, which indeed played a role of a chiral auxiliary. The highly 
diastereoselective Mukaiyama aldol reaction created the next two 
stereogenic centers and finally the 1,3-syn selective reduction produced 
the last stereocenter with high diastereoselectivity. After Raney Nickel 
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desulfurisation the enantiomer of the C(33)-C(37) dipropionate fragment of 
Amphotericin B was ready; the synthesis needed only six reaction steps 
starting from a commercially available tetrahydro thiopyran-4-one.24, 25
The dipropionate-lactone fragment of Calyculin C was a challenging target 
molecule, above all because of the anti, anti, anti stereotetrad structure. 
The intermediate lactone aldehyde 223 was used in both realized synthetic 
approaches as the key precursor.  
The convergent approach began with an anti aldol reaction between the E-
(Chx)2B-enolate of the chiral ketone 224 and the key aldehyde 223 
followed by 1,3-syn selective reduction. The PMP-acetal of 226 revealed 
the stereochemistry of the stereotetrad to be the undesired syn, anti, 
anti.62
The linear approach towards the all-anti stereotetrad was more fruitful.  
First, asymmetric crotylation between the key lactone aldehyde 223 and 
the chiral crotyl borane 227 yielded a diastereomeric mixture (6:1) of anti 
homo allylic alcohols. After ozonolysis, the β-hydroxy aldehyde 229 was 
allowed to react with (Z)-crotyl trifluorosilane 230 and only one 
diastereomer 231 was obtained as the product. The diol was finally 
converted into the corresponding ketal 232. NMR studies of the ketal 
confirmed the anti, anti, anti stereochemistry. 
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